PTC Therapeutics, Inc. announced that updates and preliminary data from ongoing clinical trials of RG7916, an oral survival motor neuron 2 (SMN2) splicing modifier in SMA patients will be presented at the International Scientific Congress on Spinal Muscular Atrophy at Jagiellonian University, Kraków, Poland from January 25-27th. The first interim analysis of survival and real-life experiences from the FIREFISH clinical trial in infants with Type 1 SMA will be presented, as well as poster presentations on SMN protein production and the safety and pharmacodynamic effects from the clinical trials in Type 2/3 SMA patients. The three ongoing clinical trials, FIREFISH, SUNFISH, and JEWELFISH, are being conducted in Type 1 and Type 2/3 SMA patients respectively. SMA is a rare genetic disorder that results in neuromuscular disability beginning in infancy and is the leading inherited cause of mortality in infants and young children.